Impact of CINV

Prevent CINV right from the start

  • Prevention in cycle 1 is associated with reduced incidence of CINV in subsequent cycles1

Compliance with antiemetic guidelines makes a significant difference in preventing CINV*,2

  • Among the recommended options in the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®), NK1 and 5-HT3 plus dexamethasone are suggested for HEC and MEC CINV prevention†,3

Study results (N=1,295)2:

When Patients RECEIVED guideline-consistent CINV prophylaxis as compared to guideline-inconsistent CINV prophylaxis...
Chart study results, patients more likely to avoic CINV

* Based on a prospective observational study in patients receiving single-dose HEC or MEC to evaluate adherence to antiemetic guidelines. The primary outcome measure was no CINV, defined as no emesis and no clinically significant nausea after chemotherapy.

Start before chemotherapy. Category 1: Based upon high-level evidence, there is uniform NCCN consensus that the intervention is appropriate.

The National Comprehensive Cancer Network makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.



CINV can significantly affect patients and can lead to emergency room and hospital visits3,4

Fourteen percent of patients on HEC or MEC regimens visited the hospital due to CINV.4 Of those...
65%

were inpatient admissions — the most common, and most costly, type of hospital visit for CINV4

CINV impacts patients
CINV
=chemotherapy-induced nausea and vomiting.
HEC
=highly emetogenic chemotherapy.
MEC
=moderately emetogenic chemotherapy.
NCCN
=National Comprehensive Cancer Network® (NCCN®).